Crysvita
(burosumab) Kyowa Kirin

Composition:
• Available in solution with each single-dose vial contains 10 mg/1 mL, 20 mg/1 mL, or 30 mg/1 mL of burosumab for subcutaneous injection

Indication:
• For the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.